Making Cash off School Kids - part 1
The National Curriculum, Comprehensive Sex Education, and the Business of PrEP and PEP
The national curriculum, managed by the Australian Curriculum, Assessment and Reporting Authority (ACARA), aligns itself with the United Nations’ Agenda 2030—a global blueprint for sustainable development. This alignment extends to the United Nations Educational, Scientific and Cultural Organisation (UNESCO) programs, which emphasize Comprehensive Sex Education (CSE) and Social Emotional Learning (SEL) initiatives.
ACARA’s “Cross-Curriculum Priorities” integrate these global objectives, embedding concepts such as sustainability, equity, inclusion, and diversity into every school subject. Compliance with these priorities is directly tied to school funding, making them unavoidable components of Australian education.
Third-Party Clinics and Pharmaceutical Promotion
Investigations by In Defence of Children have uncovered that Australian schools are inviting third-party sex and gender clinics to deliver CSE programs. In doing so, these clinics introduce students to pharmaceutical interventions such as Pre-Exposure Prophylaxis (PrEP) and Post-Exposure Prophylaxis (PEP), as well as a broader range of sexually transmitted infection (STI) treatments. This raises serious concerns about the intersection of education, medicalization, and corporate interests.
Comprehensive Sex Education: A Trojan Horse for Corporate Interests?
CSE is often framed as a “rights-based” approach to sexuality education, emphasizing children’s sexual rights. However, it neglects a balanced discussion of sexual health, reproduction, and overall well-being. Instead, it normalizes early sexual activity under the guise of empowerment while disregarding the diverse cultural and religious values of families.
From a business standpoint, this model functions as a “cradle-to-grave” marketing strategy, fostering a steady stream of consumers for pharmaceutical and sexual health industries. Encouraging children to engage in sexual activity early and often creates lifelong customers for STI treatments, contraception, and drugs like PrEP and PEP.
The PrEP Business Model: Normalizing Subscription-Based Drugs
PrEP is a daily medication claimed to be up to 99% effective in preventing HIV transmission. In 2018, a panel of experts recommended its inclusion on Australia’s Pharmaceutical Benefits Scheme (PBS), reducing its cost from approximately $1,000 to around $40 per month.
However, PrEP is not a one-time treatment—it is a subscription-based drug that must be taken continuously. This model ensures pharmaceutical companies a reliable, long-term customer base. More concerningly, its widespread promotion in CSE programs normalizes sexual activity detached from broader health considerations, effectively sidelining family values and parental guidance.
Agenda 2030 and the Push for PrEP in Schools
The push for PrEP in schools aligns with the United Nations’ goal of eradicating HIV/AIDS as a public health threat by 2030—a core component of Agenda 2030’s Sustainable Development Goals. While the eradication of disease is a commendable objective, the method of achieving it through the normalization of lifelong pharmaceutical dependency in children is deeply problematic. Instead of focusing on holistic health, risk avoidance, and family engagement, these initiatives prioritize global health policies that serve broader political and economic interests.
By embedding these programs within the national curriculum, ACARA is not just implementing education policies—it is facilitating a shift that fundamentally alters childhood, family dynamics, and medical ethics.
When education transforms into a vehicle for pharmaceutical marketing, we must ask: who truly benefits?